AIM: To investigate differences of clinical characteristics and disease courses between familial and sporadic inflammatory bowel disease (IBD) patients. METHODS: We obtained clinical data on Crohn's disease (CD) (n = 691) and ulcerative colitis (n = 1113) from a tertiary referral medical center between 2005 and 2012. Seventeen patients (2.5%) with CD and 27 patients (2.4%) with ulcerative colitis (UC) were identified as having a familial history of IBD, including the first and second degree relatives. For each control case, three times the number of age-, sex-, and diagnosis year-matched CD and UC patients, without a family history of IBD, were randomly selected in this case control study. RESULTS: There were no significant differences in age or main symptom at diagnosis, extraintestinal manifestation, location/extent, behavior of disease activity, number of hospitalizations, number of operations, operation type, number of relapses, or oral medical treatment between familial and sporadic CD and UC patients. Median (min-max) follow-up periods after diagnosis of familial CD and sporadic CD patients were 84 (24-312) and 36 (8-240) mo, respectively (P = 0.008). Familial CD patients more frequently used anti-tumor necrosis factor (TNF) antibodies compared to sporadic CD patients (17.6% vs 0%, P = 0.014). CONCLUSION: In conclusion, a family history of IBD does not seem to be an important predictive factor affecting clinical characteristics or disease course even if there is a more frequent use of anti-TNF antibodies in familial CD patients compared to sporadic CD patients.
AIM: To investigate differences of clinical characteristics and disease courses between familial and sporadic inflammatory bowel disease (IBD) patients. METHODS: We obtained clinical data on Crohn's disease (CD) (n = 691) and ulcerative colitis (n = 1113) from a tertiary referral medical center between 2005 and 2012. Seventeen patients (2.5%) with CD and 27 patients (2.4%) with ulcerative colitis (UC) were identified as having a familial history of IBD, including the first and second degree relatives. For each control case, three times the number of age-, sex-, and diagnosis year-matched CD and UC patients, without a family history of IBD, were randomly selected in this case control study. RESULTS: There were no significant differences in age or main symptom at diagnosis, extraintestinal manifestation, location/extent, behavior of disease activity, number of hospitalizations, number of operations, operation type, number of relapses, or oral medical treatment between familial and sporadic CD and UC patients. Median (min-max) follow-up periods after diagnosis of familial CD and sporadic CDpatients were 84 (24-312) and 36 (8-240) mo, respectively (P = 0.008). Familial CDpatients more frequently used anti-tumor necrosis factor (TNF) antibodies compared to sporadic CDpatients (17.6% vs 0%, P = 0.014). CONCLUSION: In conclusion, a family history of IBD does not seem to be an important predictive factor affecting clinical characteristics or disease course even if there is a more frequent use of anti-TNF antibodies in familial CDpatients compared to sporadic CDpatients.
Authors: Vared Pinsk; Daniel A Lemberg; Karan Grewal; Collin C Barker; Richard A Schreiber; Kevan Jacobson Journal: Am J Gastroenterol Date: 2007-03-22 Impact factor: 10.864
Authors: William J Sandborn; Jean-Frederic Colombel; Bruce E Sands; Paul Rutgeerts; Stephan R Targan; Remo Panaccione; Brian Bressler; Karl Geboes; Stefan Schreiber; Richard Aranda; Sheila Gujrathi; Allison Luo; Yun Peng; Luisa Salter-Cid; Stephen B Hanauer Journal: Gastroenterology Date: 2012-04-12 Impact factor: 22.682
Authors: Richard B Gearry; Ann K Richardson; Christopher M Frampton; Andrew J Dodgshun; Murray L Barclay Journal: J Gastroenterol Hepatol Date: 2010-01-14 Impact factor: 4.029
Authors: Brian G Feagan; William J Sandborn; Ulrich Mittmann; Simon Bar-Meir; Geert D'Haens; Marc Bradette; Albert Cohen; Chrystian Dallaire; Terry P Ponich; John W D McDonald; Xavier Hébuterne; Pierre Paré; Pavel Klvana; Yaron Niv; Sandro Ardizzone; Olga Alexeeva; Alaa Rostom; Gediminas Kiudelis; Johannes Spleiss; Denise Gilgen; Margaret K Vandervoort; Cindy J Wong; Guang Yong Zou; Allan Donner; Paul Rutgeerts Journal: JAMA Date: 2008-04-09 Impact factor: 56.272
Authors: Ana Gutiérrez; Pedro Zapater; Elena Ricart; María González-Vivó; Jordi Gordillo; David Olivares; Isabel Vera; Míriam Mañosa; Javier P Gisbert; Mariam Aguas; Eugenia Sánchez-Rodríguez; Maia Bosca-Watts; Viviana Laredo; Blau Camps; Ignacio Marín-Jiménez; Yamile Zabana; María Dolores Martín-Arranz; Roser Muñoz; Mercè Navarro; Eva Sierra; Lucía Madero; Milagros Vela; José Lázaro Pérez-Calle; Empar Sainz; Xavier Calvet; Lara Arias; Victor Morales; Fernando Bermejo; Luis Fernández-Salazar; Manuel Van Domselaar; Luisa De Castro; Cristina Rodríguez; Carmen Muñoz-Villafranca; Rufo Lorente; Montserrat Rivero; Eva Iglesias; Belén Herreros; David Busquets; Joan Riera; María Pilar Martínez-Montiel; Marta Roldón; Oscar Roncero; Esther Hinojosa; Mónica Sierra; Jesús Barrio; Ruth De Francisco; José Huguet; Olga Merino; Daniel Carpio; Daniel Ginard; Fernando Muñoz; Marta Piqueras; Pedro Almela; Federico Argüelles-Arias; Guillermo Alcaín; Luis Bujanda; Noemí Manceñido; Alfredo J Lucendo; Pilar Varela; Iago Rodríguez-Lago; Laura Ramos; Laura Sempere; Eva Sesé; Manuel Barreiro-de Acosta; Eugeni Domènech; Rubén Francés Journal: Front Med (Lausanne) Date: 2022-02-01